ATE518846T1 - 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten - Google Patents

2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten

Info

Publication number
ATE518846T1
ATE518846T1 AT08841479T AT08841479T ATE518846T1 AT E518846 T1 ATE518846 T1 AT E518846T1 AT 08841479 T AT08841479 T AT 08841479T AT 08841479 T AT08841479 T AT 08841479T AT E518846 T1 ATE518846 T1 AT E518846T1
Authority
AT
Austria
Prior art keywords
pain
treatment
antagonists suitable
trpvl antagonists
aminooxazole
Prior art date
Application number
AT08841479T
Other languages
English (en)
Inventor
Richard J Perner
John R Koenig
Stanley Didomenico
Erol Bayburt
Jerome Daanen
Arthur Gomtsyan
Michael E Kort
Philip R Kym
Anil Vasudevan
Robert Schmidt
Eric Voight
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE518846T1 publication Critical patent/ATE518846T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08841479T 2007-10-25 2008-10-25 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten ATE518846T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98249007P 2007-10-25 2007-10-25
US12/256,931 US7998993B2 (en) 2007-10-25 2008-10-23 TRPV1 antagonists
PCT/US2008/081229 WO2009055749A1 (en) 2007-10-25 2008-10-25 2-aminooxazole derivatives as trpvl antagonists useful for treating pain

Publications (1)

Publication Number Publication Date
ATE518846T1 true ATE518846T1 (de) 2011-08-15

Family

ID=40227493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08841479T ATE518846T1 (de) 2007-10-25 2008-10-25 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten

Country Status (9)

Country Link
US (1) US7998993B2 (de)
EP (2) EP2220059B1 (de)
JP (1) JP2011500852A (de)
CN (1) CN101835762A (de)
AT (1) ATE518846T1 (de)
CA (1) CA2702976A1 (de)
MX (1) MX2010004495A (de)
TW (1) TW200934487A (de)
WO (1) WO2009055749A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
EP2421980A2 (de) * 2009-04-23 2012-02-29 Transposagen Biopharmaceuticals, Inc. Gentechnisch veränderte rattenmodelle für krebs
EP2449112A1 (de) 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für schwere kombinierte immundefizienz (scid)
EP2460016A2 (de) * 2009-07-30 2012-06-06 Transposagen Biopharmaceuticals, Inc. Genetisch modifizierte rattenmodelle für die pharmakokinetik
WO2011017518A2 (en) * 2009-08-05 2011-02-10 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for drug metabolism
US8602579B2 (en) 2009-09-25 2013-12-10 Cree, Inc. Lighting devices including thermally conductive housings and related structures
CA2859283C (en) 2011-12-16 2021-03-09 Transposagen Biopharmaceuticals, Inc. Trpc4 modulators for use in the treatment or prevention of pain
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
CN118812481A (zh) 2019-08-23 2024-10-22 持田制药株式会社 杂环亚基乙酰胺衍生物的制造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151440A (en) * 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
MX2007014048A (es) * 2005-05-11 2008-02-05 Abbott Lab Antagonistas del receptor vaniloide subtipo 1 (vr1) y usos de los mismos.

Also Published As

Publication number Publication date
TW200934487A (en) 2009-08-16
EP2412372A1 (de) 2012-02-01
WO2009055749A1 (en) 2009-04-30
CN101835762A (zh) 2010-09-15
JP2011500852A (ja) 2011-01-06
HK1147493A1 (en) 2011-08-12
EP2220059A1 (de) 2010-08-25
MX2010004495A (es) 2010-05-05
EP2220059B1 (de) 2011-08-03
US20090124666A1 (en) 2009-05-14
CA2702976A1 (en) 2009-04-30
US7998993B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
ATE518846T1 (de) 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
EA201100748A1 (ru) Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
CY1117045T1 (el) Ενωσεις κινουκλιδινης ως προσδετες του νικοτινικου υποδοχεα ακετυλχολινης αλφα-7
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MX2010007391A (es) Antagonistas de trpa1.
CY1110901T1 (el) Στερεοϊσομερεις ενωσεις και μεθοδοι για την αγωγη γαστρεντερικων διαταραχων και διαταραχων του κεντρικου νευρικου συστηματος
EA200802054A1 (ru) Ингибиторы фермента
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EA201000550A1 (ru) Производные тиазола
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
EA200600860A1 (ru) Производные n-тиазол-2-илбензамида
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
EA200901179A1 (ru) Замещённые тетрагидрохинолины
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
CO5640133A2 (es) Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de la serotonina
ATE347883T1 (de) Verwendung von n-(2-aryl-propionyl)-sulfonamiden zur behandlung von rückenmarkverletzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties